DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for bacteriemia — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBacteriemia maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside bacteriemia in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis — Linezolid has a real, experimentally solved structure in complex with this target (PDB 5NZ0, 1.825 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet zlddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NZ0 · 1.825 Å · ligand Linezolid (ZLD). Experimental structure, not a prediction.
What the evidence adds up to
In a 2003 trial, 113 children with bacteraemia (81 on linezolid, 32 on vancomycin) were studied. Clinical cure rates for catheter-related bacteraemia were 84.8% for linezolid and 80.0% for vancomycin; for bacteraemia of unknown source, rates were 79.2% and 69.2% respectively. Neither difference was statistically significant. Fewer linezolid-treated patients had drug-related adverse events (19.4% vs 28.3%), but this also was not significant. The authors concluded linezolid was as effective as vancomycin and well tolerated.
Two 1989 case reports described bacteraemic patients who failed to respond to daptomycin at the recommended dosage, despite apparent in vitro sensitivity. The drug’s sponsor was said to be revising dosage guidelines. A 2014 case report claimed the first successful treatment of daptomycin-nonsusceptible Enterococcus faecium bacteraemia with daptomycin monotherapy, but this is a single case with no control and the authors note that optimal therapy for such infections remains unclear.
The evidence for daptomycin in bacteraemia is limited to two early failures and one later single-case success against a resistant organism. The linezolid trial is the only randomised comparison, and it showed equivalence to vancomycin, not superiority. No large, modern, randomised trial has tested daptomycin against standard care for bacteraemia. What is missing is a properly powered trial with clearly defined patient stratification (e.g., by pathogen susceptibility, source of bacteraemia, and prior antibiotic exposure) and adequate funding to support such a study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Pediatric Infectious Disease Journal · 2003 · 70 citations
Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens
AbstractBACKGROUND: Nosocomial infections, particularly hospital-acquired pneumonia (HAP) and bacteremia, are an increasing concern in pediatric hospitals and pediatric intensive care units. Gram-positive pathogens are a leading cause of these infections in children. Linezolid is well-tolerated and as effective as vancomycin in the treatment of these infections in adults. OBJECTIVE: To evaluate the clinical effectiveness and safety of iv/oral linezolid and iv vancomycin in children with resistant Gram-positive HAP or bacteremia. METHODS: Hospitalized children <12 years of age were randomized 2:1 to linezolid or vancomycin. Patients received linezolid 10 mg/kg iv every 8 h with the option to change treatment to oral linezolid suspension 10 mg/kg every 8 h or iv vancomycin 10 to 15 mg/kg every 6 to 24 h. Clinical response was evaluated at follow-up. Results from an analysis of patients with HAP or bacteremia are presented. RESULTS: Thirty-nine patients (linezolid, 23; vancomycin, 16) with HAP and 113 patients with bacteremia (linezolid, 81; vancomycin, 32) were included in the intent-to-treat group. Clinical cure rates for clinically evaluable patients with HAP did not differ between treatment groups (linezolid, 90.0% and vancomycin, 100%; P = 0.305). No significant difference was seen in clinical cure rates in the clinically evaluable population between the linezolid and vancomycin groups for patients with catheter-related bacteremia (84.8 and 80.0%, respectively; P = 0.716) or patients with bacteremia of unknown source (79.2 and 69.2%, respectively; P = 0.501). In this subset fewer linezolid-treated patients had drug-related adverse events than did vancomycin-treated patients (19.4% vs. 28.3%; P = 0.230). Similar percentages of patients with laboratory abnormalities, including selected hematologic parameters, were seen in both treatment groups. CONCLUSIONS: Intravenous/oral linezolid was well-tolerated and as effective as vancomycin in treating children with resistant Gram-positive HAP or bacteremia.
Suboptimal Effect of Daptomycin in the Treatment of Bacteremias
AbstractWe have reported two cases involving bacteremic patients who failed to respond adequately to the investigational agent daptomycin. Despite apparent sensitivity of the organisms, therapy was unsuccessful in both patients using the recommended dosage. The sponsor of daptomycin is currently reevaluating the recommendation and may be revising their dosage guidelines in the future.
Journal of Microbiology and Infectious Diseases · 2014 · 0 citations · open access
Daptomycin for the treatment of daptomycin nonsusceptible Enterococcus faecium bacteremia
AbstractDilek Yildiz Sevgi, Alper Gunduz, Ahmet Şanlı Konuklar, Murat Musluman, Feyzullah Tuncer, Okan Derin, Banu Bayraktar, Nuray Uzun The best therapeutic options for serious infections due to daptomycin nonsusceptible Enterococcus faecium (DNSE) remain unclear. We report the use of daptomycin for the treatment of DNSE bacteremia. To our knowledge, it is the fırst case of DNSE infection which successfully treated with daptomycin monotherapy in the literature.
DOAJ (DOAJ: Directory of Open Access Journals) · 2014 · 0 citations
Daptomycin for the treatment of daptomycin nonsusceptible Enterococcus faecium bacteremia
AbstractThe best therapeutic options for serious infections due to daptomycin nonsusceptible Enterococcus faecium (DNSE) remain unclear. We report the use of daptomycin for the treatment of DNSE bacteremia. To our knowledge, it is the fırst case of DNSE infection which successfully treated with daptomycin monotherapy in the literature. J Microbiol Infect Dis 2014;4(1): 36-38 [J Microbiol Infect Dis 2014; 4(1.000): 36-38]
Disease module: DeepOracle (Open Targets). Approved indication: ChEMBL drug_indication (max_phase=4). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
